ACM
IMUC

Alethea Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Alethea Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-275
Closed -$5K – 104
2015
Q3 		$5K Buy
+275
New +$5.01K 0.01% 63

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alethea Capital Management's IMUC Position: Q4 2015 in Review

Alethea Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2015, closing a stake of 275 shares — an estimated $5K sold.

Alethea Capital Management first reported a position in IMUC in Q3 2015 and held it in 1 quarter. The position peaked at $5K in Q3 2015. 28 funds tracked by Wall St. Rank hold IMUC as of Q4 2015.

  • Alethea Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2015 after selling out during the quarter.
  • Alethea Capital Management sold 275 ImmunoCellular Therapeutics, Ltd. shares in Q4 2015, an estimated $5K.
  • Alethea Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2015 and held it in 1 quarter.
  • Alethea Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $5K in Q3 2015.
  • 28 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2015.

Based on Alethea Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.